Recruiting

CoFI System

Sponsor:

CorFlow Therapeutics AG

Code:

NCT06909578

Conditions

Microvascular Obstruction (MVO)

STEMI - ST Elevation Myocardial Infarction

PPCI

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

CorFlow Controlled Flow Infusion System - CoFI™

Study Details

Brief summary:

A prospective, multicenter, international single-arm, pivotal clinical study designed to validate the performance of the CoFI system in detecting MVO in STEMI subjects, as confirmed by CMRI. The study will be conducted in accordance with the Declaration of Helsinki, EN ISO 14155:2020, local and national regulations.

Each study site will receive support from a sponsor-certified proctor during the learning curve to ensure consistent and accurate application of the CoFI system.

Conditions

Microvascular Obstruction (MVO)

STEMI - ST Elevation Myocardial Infarction

PPCI

Study ID

NCT06909578

Start date

Sep 1, 2025

Status verified date

Nov, 2026

Completion date

Dec 31, 2027

Anticipated

Primary completion date

Dec 31, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Clinical:

1. Subject ≥18 years of age
2. Ability to provide written informed consent according to GCP and governing regulations
3. Diagnosis of acute anterior STEMI
4. First Medical Contact (FMC) to balloon time ≤ 6 hours. PPCI \& Angiographic

1\. Culprit lesion in the LAD 2. COFI ballon can be placed according to IFU 3. Required stent diameter ≥ 2.75 mm and ≤ 5mm 4. Required stent length ≥ 15 mm 5. Successful PPCI Procedure as documented by <50% diameter residual angiographic stenosis within all treated culprit lesions with TIMI 2 or 3 flow and no presence of a post-intervention non-stented coronary dissection or perforation.

Exclusion Criteria

Clinical:

1. Cardiogenic shock
2. Thrombolytic therapy administered for this STEMI
3. Contraindication to CMRI

1. Cardiac pacemaker or implantable defibrillator;
2. Non-MRI compatible aneurysm clip;
3. Neural Stimulator (i.e., TENS unit);
4. Any implanted or magnetically activated device (insulin pump);
5. Any type of non-MRI compatible ear implant;
6. Metal shavings in the orbits;
7. Any metallic foreign body, shrapnel, or bullet in a location which the physician feels would present a risk to the subject;
8. Any history indicating contraindication to MRI
9. Inability to follow breath hold instructions or to maintain a breath hold for >15 seconds; and
10. Known hypersensitivity or contraindication to gadolinium con-trast.
4. Subject with previous Q-Wave MI and/or known cardiomyopathy (ischemic and non ischemic), ventricular pseudoaneurysm, Ventricular Septal Defect, severe mitral valve regurgitation (with or without papillary muscle rupture), severe known cardiac valvular stenosis or insufficiency, pericardial disease
5. Major bleeding ≤ 30d prior to intervention
6. Major surgery ≤ 30d prior to intervention
7. TIA or stroke ≤ 30d prior to intervention
8. Heart failure with inotrope support and/or consideration for LVAD or heart transplant
9. Presence of an intra-aortic balloon pump
10. Known severe renal disease with creatinine > 2.5 mg/dL and/or eGFR < 30 mL/min/1.73 m2
11. Subject has other medical illness (e.g., cancer, dementia) or known history of substance abuse (alcohol, cocaine, heroin, etc.) that may cause non-compliance with the CIP, confound the data interpretation, or is associated with limited life expectancy of less than one year
12. Current participation in another clinical study
13. Pregnancy

PPCI \& Angiographic:

1. CABG of LAD
2. Unsuitable target vessel anatomy (excessive tortuosity, diffuse disease, or moderate/heavy calcification)
3. Cardiac condition preventing the use of the CoFI System
4. Any angiographic post stenting condition that according to the physician requires treatment targeting no-reflow/MVO
5. Cardiac condition mandating elective PCI/CABG procedure prior to CMRI

Study Design

Enrollment

236 participants

Anticipated

Intervention Model

Single group

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

other: Adult subjects presenting with STEMI in the LAD undergoing PPCI

Interventions

CorFlow Controlled Flow Infusion System - CoFI™

The CorFlow CoFI™ System is intended to assess the dynamic microvascular resistance and to treat microvascular obstruction in the coronary vasculature of patients following PCI with stent placement.

Primary outcome measure

  • Primary Effectiveness Endpoint [ Time Frame: From enrollment to the end of treatment at 6 Months ]

Central Contacts and Locations

Central contacts

Locations

Ronald Reagan UCLA Medical Center

Recruiting

Los Angeles, California, United States, 90095

ChristianaCare - Christiana Hospital

Recruiting

Newark, Delaware, United States, 19718

Trinity Health Ann Arbor Hospital

Recruiting

Ypsilanti, Michigan, United States, 48197

Allina Health Mercy Hospital

Recruiting

Coon Rapids, Minnesota, United States, 55433

Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital

Recruiting

Minneapolis, Minnesota, United States, 55407

Montefiore Medical Center

Recruiting

The Bronx, New York, United States, 10467

Atrium Health Carolinas Medical Center

Recruiting

Charlotte, North Carolina, United States, 28203

The Christ Hospital

Recruiting

Cincinnati, Ohio, United States, 45219

OhioHealth Riverside Methodist Hospital

Recruiting

Columbus, Ohio, United States, 43214

WVU Medicine - J.W. Ruby Memorial Hospital

Recruiting

Morgantown, West Virginia, United States, 26506

Aurora St. Luke's Medical Center

Recruiting

Milwaukee, Wisconsin, United States, 53215

More Information

Sponsor

CorFlow Therapeutics AG

Last update posted

Nov 20, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-21. This information was provided to ClinicalTrials.gov by CorFlow Therapeutics AG on 2026-11-20. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.